CENBF OTC
CEN Biotech, Inc.
1W: +200.0%
1M: +200.0%
3M: +200.0%
YTD: +200.0%
1Y: +200.0%
3Y: -99.0%
5Y: -100.0%
$0.00
+0.00 (+200.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$987K
+57.5% ▲
Gross Profit
$498K
-20.6% ▼
Operating Income
-$1M
+93.4% ▲
Net Income
-$2M
+92.0% ▲
EPS (Diluted)
$-0.02
+94.8% ▲
EBITDA
-$773K
+95.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $627K | $987K |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +57.5% |
| Cost of Revenue | $4M | $3M | $436K | $0 | $489K |
| Gross Profit | -$4M | -$3M | -$436K | $627K | $498K |
| Gross Margin | — | — | — | 100.0% | 50.5% |
| R&D Expenses | $41K | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3M | $3M | $2M | $18M | $2M |
| Operating Expenses | $3M | $3M | $2M | $20M | $2M |
| Operating Income | -$3M | -$3M | -$2M | -$19M | -$1M |
| Operating Margin | — | — | — | -3037.0% | -128.2% |
| Interest Expense | $3M | $3M | $4M | $847K | $253K |
| Income Before Tax | -$8M | -$6M | $14M | -$19M | -$2M |
| Tax Expense | -$289K | $0 | $0 | -$36K | $0 |
| Net Income | -$8M | -$6M | $14M | -$19M | -$2M |
| Net Margin | — | — | — | -3015.6% | -153.5% |
| EPS (Diluted) | $-0.30 | $-0.35 | $0.45 | $-0.45 | $-0.02 |
| EBITDA | -$4M | -$2M | $18M | -$18M | -$773K |
| Shares Outstanding | 25M | 26M | 33M | 42M | 65M |